NCT03780582 is a NA clinical trial of AI-human interaction in Lung Cancer, sponsored by Ensemble Group Holdings, LLC.

Who is sponsoring NCT03780582?

NCT03780582 is sponsored by Ensemble Group Holdings, LLC.

What drugs are being tested in NCT03780582?

Interventions in NCT03780582: AI-human interaction.

What condition does NCT03780582 study?

NCT03780582 studies Lung Cancer.

Is NCT03780582 still recruiting?

NCT03780582 is currently status unknown. Last updated 23 July 2019.

Last reviewed 2019-07-23 · How we verify

NCT03780582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Use of Diagnostic AI for Lung Cancer in Practice

Status unknown NA Last updated 23 July 2019

What this trial tests

NA trial testing AI-human interaction in Lung Cancer in 15 participants. Status unknown.

Timeline

14 December 2018

Primary endpoint
15 December 2019

15 December 2019

Quick facts

Lead sponsor	Ensemble Group Holdings, LLC
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	diagnostic
Enrollment	15
Start date	14 December 2018
Primary completion	15 December 2019
Estimated completion	15 December 2019
Sites	1 location across Hong Kong

Drugs / interventions tested

AI-human interaction

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Ensemble Group Holdings, LLC

Who can join

Eligibility, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates ways of improving radiologists performance of the classification of CT-scans as cancerous or non-cancerous. Participants interact with an AI to classify CT-scans under three different conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Ensemble Group Holdings, LLC trials

Trials by the same sponsor.

NCT04561024 — Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03780582 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ensemble Group Holdings, LLC
Last refreshed: 23 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing